TLDR
- Tempus AI shares jumped approximately 7% to reach $82.24 following impressive quarterly results.
- The company reported $382.49 million in revenue, representing a 22% year-over-year increase and surpassing analyst forecasts.
- Tempus posted a narrower-than-anticipated loss of $0.04 per share.
- Founder and CEO Eric Lefkofsky offloaded 250,000 shares valued at $19.4 million through a pre-arranged 10b5-1 trading plan.
- Analyst sentiment remains divided, with a consensus Hold recommendation and an average target of $69.63.
Tempus AI (TEM) shares surged 7% this week, reaching $82.24 as the healthcare technology firm delivered an earnings beat that overshadowed significant insider stock sales. The company’s quarterly performance exceeded Wall Street projections across key financial metrics.
The stock has recovered 30% year-to-date, bouncing back from a steep decline that wiped out nearly half its value from peak levels.
Quarterly revenue reached $382.49 million, representing a robust 22% jump compared to the year-ago period.
On an adjusted basis, Tempus AI reported a loss of just $0.04 per share. Wall Street had forecasted a significantly larger loss of $0.14 per share.
Despite the positive momentum, the company remains unprofitable. Net losses over the past twelve months totaled $254.4 million.
Executive Stock Sales Through Pre-Arranged Programs
Founder and CEO Eric Lefkofsky divested 250,000 shares on September 22 at an average selling price of $77.47. The transaction generated approximately $19.4 million and reduced his direct ownership stake by roughly 71%.
Chief Accounting Officer Ryan Bartolucci participated in the selling activity as well. He sold 7,062 shares for $529,650 on September 17, reducing his direct holdings to 60,804 shares.
Additional executives followed suit. CEO Ryan Fukushima disposed of 700 shares valued at $49,000, while EVP Andrew Polovin sold 2,951 shares generating $221,325.
Each of these transactions occurred under Rule 10b5-1 trading plans. These pre-established programs ensure sales aren’t influenced by material non-public information.
During the last three months, company insiders collectively sold approximately $73.1 million in Tempus AI shares. Despite these sales, insiders maintain roughly 24% ownership of the firm.
Analyst Perspectives on Tempus AI
Wall Street remains divided on Tempus AI, with eleven analysts assigning Buy ratings, nine recommending Hold positions, and two advising to Sell.
This breakdown translates to a consensus Hold recommendation. The mean price target of $69.63 falls below current trading levels.
Several research firms have recently updated their outlooks. BTIG Research increased its price target from $70 to $80 while reiterating a Buy rating.
HC Wainwright upgraded its target from $56 to $66, also keeping a Buy recommendation. Raymond James established an $80 price objective.
Other analysts take a more cautious stance. UBS Group initiated coverage with a Neutral rating and $70 target price.
Stifel Nicolaus lowered its target from $60 down to $50 with a Hold rating. Wolfe Research launched coverage with a Peer Perform designation.
Trading activity intensified during the recent rally. Thursday’s session recorded approximately 8.5 million to 10.7 million shares traded, substantially exceeding the typical daily volume of around 6.1 million.
The company’s market valuation currently ranges between $14 billion and $15 billion across recent sessions. Its 52-week trading range extends from $40.77 to $104.32.
Institutional investors control 24.22% of outstanding shares. Notable recent activity includes Whittier Trust Co., which expanded its position by 190% during Q1, and CoreCap Advisors, which increased its holdings by nearly 293% in Q2.
Tempus AI operates a platform specializing in oncology and precision medicine solutions. The system integrates clinical workflows with diagnostic laboratory capabilities and analytical tools utilized by healthcare organizations nationwide.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
